Daily Stock Analysis, FATE, Fate Therapeutics Inc, priceseries

Fate Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
21.00
Close
21.54
High
22.61
Low
20.91
Previous Close
20.45
Daily Price Gain
1.09
YTD High
22.61
YTD High Date
Jul 12, 2019
YTD Low
11.70
YTD Low Date
Jan 2, 2019
YTD Price Change
8.01
YTD Gain
59.20%
52 Week High
22.61
52 Week High Date
Jul 12, 2019
52 Week Low
8.64
52 Week Low Date
Jul 31, 2018
52 Week Price Change
9.68
52 Week Gain
81.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
2.94
Mar 7. 2017
3.98
17 Trading Days
35.43%
Link
LONG
Aug 28. 2017
3.22
Sep 20. 2017
4.14
16 Trading Days
28.65%
Link
LONG
Dec 20. 2017
4.51
Jan 16. 2018
6.60
16 Trading Days
46.32%
Link
LONG
Jan 18. 2018
7.18
Feb 2. 2018
8.79
11 Trading Days
22.42%
Link
LONG
Feb 16. 2018
8.76
Mar 13. 2018
12.14
16 Trading Days
38.64%
Link
LONG
Apr 10. 2018
10.06
Apr 27. 2018
11.29
13 Trading Days
12.18%
Link
LONG
May 16. 2018
10.18
May 30. 2018
11.01
9 Trading Days
8.12%
Link
LONG
Jun 12. 2018
11.77
Jun 15. 2018
12.56
3 Trading Days
6.75%
Link
LONG
Sep 18. 2018
12.20
Oct 5. 2018
15.15
13 Trading Days
24.18%
Link
LONG
Nov 26. 2018
13.49
Dec 14. 2018
15.35
13 Trading Days
13.82%
Link
LONG
Jan 4. 2019
14.78
Jan 18. 2019
15.69
10 Trading Days
6.14%
Link
LONG
Mar 7. 2019
16.11
Mar 22. 2019
17.10
11 Trading Days
6.12%
Link
LONG
May 14. 2019
17.28
May 23. 2019
18.36
7 Trading Days
6.28%
Link
LONG
Jun 14. 2019
17.83
Jun 24. 2019
19.09
6 Trading Days
7.09%
Link
Company Information
Stock Symbol
FATE
Exchange
NasdaqGM
Company URL
http://www.fatetherapeutics.com
Company Phone
858.875.1803
CEO
J. Scott Wolchko
Headquarters
California
Business Address
3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434316
About

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. Fate Therapeutics was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.